

Table 7: Estimated patient numbers and cost

	Year 1	Year 2	Year 3
Number of patients with MSI-H/dMMR tumours*	5 to 9	5 to 9	5 to 9
Scenario without nivolumab			
Range of costs without nivolumab (all patients treated with chemotherapy)†	¶¶	¶¶	¶¶
Scenario with nivolumab			
Costs with MSI-H/dMMR positive patients treated with nivolumab†	¶¶	¶¶	¶¶
Budget impact	¶¶	¶¶	¶¶
*Range based on lowest and highest incidence estimate			
†Medicine acquisition cost plus administration costs from National Schedule of NHS Costs 2021-22			
¶¶ confidential data removed			